Presentation
AB0780 SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, FUTURE 2. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017.
The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology
(2017)
Disciplines
Publication Date
June, 2017
Citation Information
P Emery, I McInnes, Philip Mease and et.al.. "AB0780 SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, FUTURE 2. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, June 2017." The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology (2017) Available at: http://works.bepress.com/philip-mease/235/